These data argue that pharmacological inhibition of IL-4Rα signalling, currently being developed for treatment of asthma and inflammatory bowel disease (28,29), could have deleterious consequences for future ‘sporadic’ CRC risk and any therapy involving IL-4R antagonism requires careful long-term evaluation in order to monitor colorectal adenoma and CRC risk. This evidence concerns the gene IL4R and inflammatory bowel disease.